Accreditation Statement

The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit

The National Psoriasis Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This program is supported by educational grants from Celgene Corporation, Mallinkrodt Pharmacueticals, Novartis Pharmaceuticals Corporation and Valeant Pharmaceuticals.

Target Audience

Phyisicans, Residents, Fellows, Allied Healthcare Professionals

Learning Objectives

After completing this activity, participants should be able to:

Discuss the efficacy and safety of newly approved therapies for psoriasis.

Discuss the efficacy and safety of promising therapies in the pipeline for psoriasis.

Review updates in the comorbidities of psoriasis.

Course summary

Available credit:

4.00AMA PRA Category 1 Credit™

Accreditation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint providership of Oregon Health & Science University (OHSU) and the National Psoriasis Foundation. OHSU is accredited by the ACCME to provide CME for physicians.

Credit

OHSU School of Medicine, Division of CME, designates this live activity for a maximum of 4.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.